# OnCo record stemcentrx (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/stemcentrx/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "stemcentrx" ;
  schema:name "Stemcentrx"@en ;
  schema:alternateName "Stemcentrx, Inc."@en ;
  schema:description "Stemcentrx was a privately held company that developed rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate aimed at DLL3 on small cell lung cancer cells. AbbVie bought it in 2016."@en ;
  schema:url <https://onco.cc/companies/stemcentrx/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1551152/000110465916116276/a16-9837_1ex99d1.htm>, <https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/a16-11616_110q.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/rovalpituzumab-tesirine/> .